TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
TriSalus Life Sciences (NASDAQ:TLSI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $12.00. They now have a "buy" rating on the stock.
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript [Seeking Alpha]
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 [Yahoo! Finance]